Computational Drug Discovery has 737 eligible papers in the latest 30-day evidence window, up 13% from the prior window, with representative work spanning DMPKformer: An Interpretable Multimodal Deep Learning Framework for Reliable ADMET Property Prediction; Accurate prediction of activity cliff compounds based on bioactivity profiles depends on assay nearest neighbor relationships; and Artificial intelligence in QSAR modeling for predicting drug activity and toxicity.
Computational Drug Discovery shows 737 eligible recent papers and 736 commentary-ready papers in the current 30-day window, compared with 654 eligible papers in the prior window. The strongest evidence comes from 1 visible topic cluster and 8 representative papers. 1 representative paper is a preprint, so those findings should be treated as preliminary.
Computational Drug Discovery recorded 737 eligible papers in the latest 30-day window, compared with 654 in the prior 30-day window, making the current snapshot up 13% from the prior window.
737 recent vs 654 prior eligible papersComputational Drug Discovery Methods contributes 737 eligible recent papers, including 736 papers with abstracts available for commentary.
737 papers in the leading clusterThe representative set includes DMPKformer: An Interpretable Multimodal Deep Learning Framework for Reliable ADMET Property Prediction; Accurate prediction of activity cliff compounds based on bioactivity profiles depends on assay nearest neighbor relationships; Artificial intelligence in QSAR modeling for predicting drug activity and toxicity; How Advanced Artificial Intelligence Technologies Shape Drug–Drug and Drug–Target Interaction Modeling; and Ensemble Optimal Control for Managing Drug Resistance in Cancer Therapies. These papers anchor the page's claims and keep the brief tied to visible evidence.
8 representative papersComputational Drug Discovery Methods accounts for 737 eligible recent papers, including 736 commentary-ready papers in this evidence window.
737 recent eligible papersThe selected papers cover DMPKformer: An Interpretable Multimodal Deep Learning Framework for Reliable ADMET Property Prediction; Accurate prediction of activity cliff compounds based on bioactivity profiles depends on assay nearest neighbor relationships; Artificial intelligence in QSAR modeling for predicting drug activity and toxicity; and How Advanced Artificial Intelligence Technologies Shape Drug–Drug and Drug–Target Interaction Modeling. 1 representative paper is a preprint, so those findings should be treated as preliminary.
8 representative papersA recent paper from bioRxiv (Cold Spring Harbor Laboratory) in the Computational Drug Discovery Methods evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Journal of Cheminformatics in the Computational Drug Discovery Methods evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from International Journal of Chemical Research and Development in the Computational Drug Discovery Methods evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Advanced Science in the Computational Drug Discovery Methods evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from Bulletin of Mathematical Biology in the Computational Drug Discovery Methods evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from bioRxiv (Cold Spring Harbor Laboratory) in the Computational Drug Discovery Methods evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A recent paper from ChemRxiv in the Computational Drug Discovery Methods evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.
A preprint from arXiv (Cornell University) in the Computational Drug Discovery Methods evidence packet, selected because it is recent, abstract-backed, and representative of this week's topic activity.